PCL/PVA nanofibrous scaffold improve insulin-producing cells generation from human induced pluripotent stem cells

Abazari, M. F and Soleimanifar, F and Nouri Aleagha, M and Torabinejad, S and Nasiri, N and Khamisipour, G and Amini Mahabadi, J and Mahboudi, H and Enderami, S. E and Saburi, E and Hashemi, J and Kehtari, M (2018) PCL/PVA nanofibrous scaffold improve insulin-producing cells generation from human induced pluripotent stem cells. Gene, 671. pp. 50-57.

Full text not available from this repository.


Pancreatic differentiation of stem cells will aid treatment of patients with type I diabetes mellitus (T1DM). Synthetic biopolymers utilization provided extracellular matrix (ECM) and desired attributes in vitro to enhance conditions for stem cells proliferation, attachment and differentiation. A mixture of polycaprolactone and polyvinyl alcohol (PCL/PVA)-based scaffold, could establish an in vitro three-dimensional (3D) culture model. The objective of this study was investigation of the human induced pluripotent stem cells (hiPSCs) differentiation capacity to insulin-producing cells (IPCs) in 3D culture were compared with conventional culture (2D) groups evaluated at the mRNA and protein levels by quantitative PCR and immunofluorescence assay, respectively. The functionality of differentiated IPCs was assessed by C-peptide and insulin release in response to glucose stimulation test. Real-Time PCR results showed that iPSCs-IPCs expressed pancreas-specific transcription factors (Insulin, Pdx1, Glucagon, Glut2 and Ngn3). The expressions of these transcription factors in PCL/PVA scaffold were higher than 2D groups. In addition to IPCs specific markers were detected by immunochemistry. These cells in both groups secreted insulin and C-peptide in a glucose challenge test by ELISA showing in vitro maturation. The results of current study demonstrated that enhanced differentiation of IPCs from hiPSCs could be result of PCL/PVA nanofibrous scaffolds. In conclusion, this research could provide a new approach to beta-like cells replacement therapies and pancreatic tissue engineering for T1DM in the future

Item Type: Article
Subjects: QZ Pathology
Divisions: Faculty of Medicin > Department of Genetic
Depositing User: سپیده مقدسی
Date Deposited: 03 Jul 2018 08:41
Last Modified: 03 Jul 2018 08:41
URI: http://eprints.bpums.ac.ir/id/eprint/6910

Actions (login required)

View Item View Item